|
 |
VentavisThis page contains recent news articles, when available, and an overview of Ventavis but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.However, six months later, Actelion stepped in with a $420 million cash offer for CoTherix, driven primarily by the latter's PAH drug Ventavis (iloprost), ... BioWorld Online Actelion: Asahi Kasei erhält USD 91 Mio. für die Einstellung von FasudilA - Dec 22, 2009 Actelion übernahm CoTherix Anfang 2007, in erster Linie wegen des Arzneimittels Ventavis zur Behandlung von PAH. - Die Verwendung von Rho-Kinaseinhibitoren ... Godmodetrader Finanznachrichten Actelion: tribunal arbitral se prononce pour paiement 91 mio USD à Asahi (dév.2) - Dec 22, 2009 Le produit-phare de CoTherix est le Ventavis (hypertonie artérielle pulmonaire). En 2008, il a permis de générer un chiffre d'affaires de 94,6 mio CHF. Romandie.com Actelion Pharmaceuticals Ltd (CH) - Actelion announces 9-month financial ... - Oct 21, 2009 Ventavis® (iloprost) sales amounted to CHF 101.6 million for the first nine months of 2009 (9M 2008: CHF 64.5 m). This represents an increase of 50 percent ... PharmaLive.com (press release) Tracleer drives Actelion sales up 22% - Oct 20, 2009 Of the firm's other products, Ventavis (iloprost), an inhaled therapy for the treatment of PAH, leapt 57.5% to 101.6 million francs, while sales of Zavesca ... Pharma Times US HOT STOCKS: SanDisk, Yahoo, Cree Active In Late Trading - Oct 20, 2009 ...(UTHR, $41.98, -$2.42, -5.45%) slipped after Actelion posted stronger than expected US sales for its pulmonary arterial hypertension drug Ventavis, ... Wall Street Journal Actelion steigert Neunmonatsumsatz - Guidance bestätigt (AF) - Oct 19, 2009 Mit Ventavis wurde ein Umsatz von 101,6 Mio CHF erzielt, nachdem es in der Vergleichsperiode des Vorjahres noch 64,5 Mio CHF waren. ... Handelszeitung Online Actelion mit Gewinnsprung nach neun Monaten - Oct 20, 2009 Das Lungenhochdruck-Medikament Ventavis steuerte 101,6 Mio. Franken zum Umsatz des Baselbieter Unternehmens bei. In der Vorjahresperiode waren es noch 64,5 ... APA - Austria Presse Agentur Actelion 9 mois: CA +22% - 2009 att. dans le haut de la fourchette (2ème dév.) - Oct 19, 2009 Outre les ventes du Tracleer, le chiffre d'affaires sur neuf mois d'Actelion englobe des ventes de 101,6 mio CHF réalisées avec Ventavis, contre 64,5 mio ... Romandie.com Actelion: 3Q09 insgesamt erwartungsgemäss - Oct 20, 2009 Der Umsatz von Ventavis war viel stärker, möglicherweise wegen der Indikationserweiterung im August 2009. - Der Cash- EBIT liegt leicht unter unseren ... Godmodetrader Finanznachrichten TAGESÃœBERSICHT WIRTSCHAFT - Oct 20, 2009 Das Lungenhochdruck-Medikament Ventavis steuerte 101,6 Mio. Fr. zum Umsatz des Baselbieter Unternehmens bei. In der Vorjahresperiode waren es noch 64,5 Mio. ... Handelszeitung Online New Ventavis Data Presented at CHEST Meeting. - Oct 31, 2005 MONTREAL, Oct. 31 /PRNewswire-FirstCall/ -- CoTherix, Inc. today announced newly-presented data from a Phase II randomized clinical study designed to ... Free with registration - PR Newswire - AccessMyLibrary.com CoTherix Bought By Swiss Firm - Nov 20, 2006 In 2007, Actelion expects sales of the inhaled PAH drug Ventavis to contribute more than $100 million to its product revenue. PAH is a chronic, ... TheStreet.com - TheStreet.com (subscription) CoTherix's Ventavis(R) Commercially Available for the Treatment of … - Mar 22, 2005 SOUTH SAN FRANCISCO, Calif., March 22 /PRNewswire/ -- CoTherix, Inc. announced today the commercial availability of Ventavis(R) (iloprost) Inhalation ... RedOrbit CoTherix Gets Approval For Inhaled PAH Drug Ventavis - Jan 4, 2005 By Karen Pihl-Carey. Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for ... BioWorld Online - BioWorld Online CoTherix Initiates Trial of Ventavis in Combination With Sildenafil... - Mar 8, 2006 SOUTH SAN FRANCISCO, Calif., March 8 /PRNewswire-FirstCall/ -- CoTherix, Inc. today announced the initiation of a Phase III trial of Ventavis(R) (iloprost) ... $4.95 - PR Newswire - ECNext Priority Healthcare selected as a provider of Ventavis. - Feb 22, 2005 Priority Healthcare Corp has been selected by CoTherix Inc to be a full-service speciality pharmacy provider of Ventavis (iloprost) Inhalation Solution. ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Press Release: CoTherix Initiates Trial of Ventavis in Combination... - Mar 8, 2006 CoTherix Initiates Trial of Ventavis in Combination With Sildenafil for Pulmonary Arterial Hypertension. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research CoTherix Initiates Phase II Trial for Ventavis in Expanded Indication - Jun 1, 2005 SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that it has initiated a Phase II trial for its marketed product ... RedOrbit Actelion to buy CoTherix: $420 MILLION DEAL PUTS TWO … - Nov 21, 2006 CoTherix licensed Ventavis from Schering of Germany. In June this year, CoTherix also licensed the rights to develop and sell Fasudil, another treatment for ... Free with registration - San Jose Mercury News - AccessMyLibrary.com … Quadrant for Development of Extended-Release Formulation of Ventavi... - Apr 5, 2005 Ventavis is marketed by CoTherix in the US for the treatment of pulmonary ... Ventavis is the newest entry into the prostacyclin class of PAH treatments. ... RedOrbit Q2 2006 COTHERIX INC Earnings Conference Call - Part 1. - Aug 2, 2006 This spending reflects our ongoing investments in Ventavis, as well as our ... Since launch, the introduction of Ventavis has fundamentally changed the way ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com New Ventavis(R) Data to Be Presented at American Thoracic Society's … - May 16, 2005 SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- CoTherix, Inc. today announced that data on Ventavis(R) (iloprost) Inhalation Solution will be ... RedOrbit … Announce Launch of New Portable Inhalation Device to Ventavis … - Dec 13, 2005 Ventavis is indicated for the treatment of pulmonary arterial hypertension ... "The battery-operated I-neb makes Ventavis an even better therapeutic option ... RedOrbit … Release: CoTherix Announces Fourth Quarter Ventavis Sales and 2006... - Jan 19, 2006 CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue Guidance. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research CoTherix Reports Positive Clinical Data From STEP Study - Mar 8, 2005 The analysis of this study showed that the combination of Ventavis(R) ... Common adverse events that occurred more frequently in the Ventavis arm were those ... RedOrbit Q3 2006 COTHERIX INC Earnings Conference Call - Part 1. - Nov 1, 2006 This quarter we increased sales of Ventavis recording $18.4 million for the third ... I'm delighted with our progress in making the Ventavis experience ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … : CoTherix Initiates Phase II Trial for Ventavis in Expanded... - Jun 1, 2005 CoTherix Initiates Phase II Trial for Ventavis in Expanded Indication. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Actelion bids $420 million for US firm CoTherix; gains rights to... - Nov 27, 2006 The US firm markets Ventavis (iloprost), the only approved inhaled therapy for ... In 2007, Actelion expects Ventavis sales to contribute more than $100.0 ... $9.94 - Pharma Marketletter - Alacra Store Press Release: New Ventavis(R) Data to Be Presented at American … - May 16, 2005 New Ventavis(R) Data to Be Presented at American Thoracic Society's International Conference. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Third Quarter Results. - Nov 2, 2006 CoTherix currently markets Ventavis (iloprost) Inhalation Solution in the United ... "In addition to the strong sales of Ventavis, we initiated clinical ... Free with registration - M2 Presswire - AccessMyLibrary.com … : CoTherix Announces First Full Quarter of Ventavis Sales. - PR... - Aug 3, 2005 CoTherix Announces First Full Quarter of Ventavis Sales. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … & Finance; CoTherix reports increasing Ventavis sales, provides Q4... - Apr 12, 2006 2006 APR 12 - (NewsRx.com) -- CoTherix, Inc., (CTRX) reported results for its fourth quarter and year ended December 31, 2005. Net product sales from the ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: New Ventavis Data Presented at CHEST Meeting. - PR … - Oct 31, 2005 New Ventavis Data Presented at CHEST Meeting. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue … - Jan 19, 2006 SOUTH SAN FRANCISCO, Calif., Jan. 19 /PRNewswire-FirstCall/ -- CoTherix, Inc. today announced that preliminary net product sales of Ventavis(R)(iloprost) ... $4.95 - PR Newswire - ECNext … : FDA Grants Expanded Label for Ventavis. - PR Newswire | HighBeam ... - Aug 30, 2005 FDA Grants Expanded Label for Ventavis. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Company Profile Report - Jan 6, 2007 The Company began selling Ventavis (iloprost) Inhalation Solution in March 2005. Ventavis is an inhaled formulation of iloprost, a synthetic compound ... $50.00 - Revere Reports - Revere Accredo Health, Inc. Selected by CoTherix, Inc. for Ventavis Distribut... - Jan 19, 2005 Ventavis, which was recently approved by the FDA for the treatment of pulmonary arterial hypertension (World Health Organization Group I), or PAH, ... $4.95 - Business Wire - ECNext United Therapeutics shares rise on Viveta data - May 22, 2008 If approved, Viveta would likely compete with Switzerland-based Actelion Ltd.'s Ventavis, the only inhaled PAH drug on the market. ... Boston Globe Press Release: CoTherix Reports First Quarter Results. - PR Newswire... - May 3, 2006 Net product sales from the Company's Ventavis(R) Inhalation Solution in the first ... Article: CoTherix Announces First Full Quarter of Ventavis Sales. ... Pay-Per-View - PR Newswire - HighBeam Research Competitors by Product Report - Jan 6, 2007 The Company began selling Ventavis (iloprost) Inhalation Solution in March 2005. Ventavis is an inhaled formulation of iloprost, a synthetic compound ... $75.00 - Revere Reports - Revere CoTherix Announces First Full Quarter of Ventavis Sales. - Aug 3, 2005 Attained broad coverage for Ventavis from private insurance plans. -- Received preliminary reimbursement codes for Ventavis from the Center for Medicare and ... $4.95 - PR Newswire - ECNext Ventavis Launch to Expand Market for PAH Drugs; Accredo and Priority... - Apr 1, 2005 The launch of Ventavis (iloprost), expected in the next few weeks, should expand the market for drugs that treat pulmonary arterial hypertension (PAH), ... Pay-Per-View - Specialty Pharmacy News - Factiva, from Dow Jones … SELECTS ACCREDO THERAPEUTICS TO DISTRIBUTE VENTAVIS. - Mar 1, 2005 Accredo Health, Incorporated (NASDAQ: ACDO), Memphis, Tenn., has announced that one of its three primary divisions, Accredo Therapeutics, has been selected ... Entrepreneur Ventavis Scrutinized for IPF-Related Pulmonary Hypertension - Jul 7, 2005 ...by John C. Martin. A medication already approved as a therapy for people with pulmonary hypertension (PH) is about to enter a second round of clinical ... PH Neighborhood CoTherix' Ventavis debuts in USA.(Brief Article) - Mar 28, 2005 Following the December 2004 approval of the drug by the US Food and Drug Administration, CoTherix has announced the commercial availability of Ventavis ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Pulmonary Arterial Hypertension; Ventavis commercially available for... - Apr 19, 2005 2005 APR 19 - (NewsRx.com) -- CoTherix, Inc., announced the commercial availability of Ventavis (iloprost) Inhalation Solution in the US for the treatment ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Pulmonary Arterial Hypertension; Ventavis commercially available for... - Apr 22, 2005 2005 APR 22 - (NewsRx.com) -- CoTherix, Inc., announced the commercial availability of Ventavis (iloprost) Inhalation Solution in the US for the treatment ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Pulmonary Arterial Hypertension; Ventavis commercially available for... - Apr 18, 2005 2005 APR 18 - (NewsRx.com) -- CoTherix, Inc., announced the commercial availability of Ventavis (iloprost) Inhalation Solution in the US for the treatment ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Q1 2006 COTHERIX INC Earnings Conference Call - Part 1. - May 3, 2006 Upon our reaching $25 million in Ventavis sales, anticipated later in the year, ... We are making significant investments in Ventavis including the VISION, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Healthcare Selected as a Provider of Ventavis(TM). - PR Newswire |... - Feb 22, 2005 Priority Healthcare Selected as a Provider of Ventavis(TM). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix Enters Into Agreement With Quadrant for … - Apr 5, 2005 Ventavis is marketed by CoTherix in the U.S. for the treatment of pulmonary ... Ventavis is the newest entry into the prostacyclin class of PAH treatments. ... Pay-Per-View - PR Newswire - HighBeam Research CoTherix raises $35.6m for Ventavis.(Friday, February 11)(Brief... - Feb 14, 2005 Less than four months after conducting an initial public offering, CoTherix Inc. returned to the market for a follow-on offering raising $35.6 million. ... Free with registration - BioWorld Week - AccessMyLibrary.com Elaprase i Ventavis u Listi osnovnih lijekova - Nov 14, 2007 Na sjednici je odluÄ?eno o obavljanju dijagnostiÄ?kog postupka za otkrivanje metastaza PET/CT u RH, koji se do sada obavljao u inozemstvu. ... Javno.hr Press Release: CoTherix Reports Third Quarter Results. - PR Newswire... - Nov 2, 2005 Ventavis Third Quarter Revenue More than Doubles Second Quarter Levels ... Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH), ... Pay-Per-View - PR Newswire - HighBeam Research FDA Approvals: Ventavis, Kepivance, Captique - Jan 5, 2005 Jan. 5, 2005 — The US Food and Drug Administration (FDA) has approved iloprost inhalation solution for the treatment of severe pulmonary arterial ... Medscape … Hypertension; US FDA approves Ventavis for pulmonary arterial … - Jan 24, 2005 2005 JAN 24 - (NewsRx.com & NewsRx.net) -- CoTherix, Inc., (CTRX) announced that following priority review, the US Food and Drug Administration (FDA) has ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones Business & Finance; Ventavis maker reports "remarkable" year - Apr 12, 2005 2005 APR 12 - (NewsRx.com) -- CoTherix, Inc., (CTRX) reported its results for the fourth quarter and fiscal year ended December 31, 2004. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Collaborations; Pharmacy provider selected by CoTherix for Ventavis … - Feb 15, 2005 Ventavis, which was recently approved by the FDA for the treatment of pulmonary arterial hypertension (World Health Organization Group I), or PAH, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Collaborations; Pharmacy provider selected by CoTherix for Ventavis … - Feb 19, 2005 Ventavis, which was recently approved by the FDA for the treatment of pulmonary arterial hypertension (World Health Organization Group I), or PAH, ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones … Hypertension; US FDA approves Ventavis for pulmonary arterial … - Jan 30, 2005 2005 JAN 30 - (NewsRx.com & NewsRx.net) -- CoTherix, Inc., (CTRX) announced that following priority review, the US Food and Drug Administration (FDA) has ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Collaborations; Pharmacy provider selected by CoTherix for Ventavis … - Feb 14, 2005 Ventavis, which was recently approved by the FDA for the treatment of pulmonary arterial hypertension (World Health Organization Group I), or PAH, ... Pay-Per-View - Managed Care Weekly Digest - Factiva, from Dow Jones … Hypertension; US FDA approves Ventavis for pulmonary arterial … - Jan 25, 2005 2005 JAN 25 - (NewsRx.com & NewsRx.net) -- CoTherix, Inc., (CTRX) announced that following priority review, the US Food and Drug Administration (FDA) has ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones CoTherix Reports First Quarter Results. - May 3, 2006 Net product sales from the Company's Ventavis(R) Inhalation Solution in the first ... Recent Accomplishments -- Achieved first quarter Ventavis net sales of ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: CoTherix Reports First Quarter Results. - PR Newswire... - May 2, 2005 ..."We are encouraged by the demand for Ventavis to date. Patients are being placed on Ventavis therapy and we are seeing reimbursement by some of the largest ... Pay-Per-View - PR Newswire - HighBeam Research Ventavis Treatment Diary - Sep 20, 2005 Using a Treatment Diary will help you anticipate your side effects and identify patterns of side effects. You will be better able to plan your life, ... PH Neighborhood Press Release: CoTherix Reports Positive Clinical Data From STEP... - Mar 8, 2005 The analysis of this study showed that the combination of Ventavis(R) (iloprost) ... Article: CoTherix Initiates Trial of Ventavis in Combination With ... ... Pay-Per-View - PR Newswire - HighBeam Research CoTherix Reports First Quarter Results. - May 2, 2005 ..."We are encouraged by the demand for Ventavis to date. Patients are being placed on Ventavis therapy and we are seeing reimbursement by some of the largest ... $4.95 - PR Newswire - ECNext CoTherix Reports Third Quarter Results. - Nov 2, 2005 Ventavis is indicated for the treatment of pulmonary arterial hypertension ... The second allowed for the administration of Ventavis using the I-neb(TM), ... Free with registration - PR Newswire - AccessMyLibrary.com Expanded label for CoTherix' Ventavis.(pulmonary arterial hypertension... - Sep 5, 2005 US drugmaker CoTherix has received approval from the Food and Drug Administration to modify the label for its pulmonary arterial hypertension drug Ventavis ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Finance; Ventavis maker announces partial exercise of over-allotment ... - Mar 14, 2005 2005 MAR 14 - (NewsRx.com) -- CoTherix, Inc., announced that the underwriters of its follow-on offering have exercised their over-allotment option to ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Finance; Ventavis maker announces partial exercise of over-allotment ... - Mar 18, 2005 2005 MAR 18 - (NewsRx.com) -- CoTherix, Inc., announced that the underwriters of its follow-on offering have exercised their over-allotment option to ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Finance; Ventavis maker announces follow-on offering of 4,000,000 … - Mar 7, 2005 2005 MAR 7 - (NewsRx.com & NewsRx.net) -- CoTherix, Inc., (CTRX) announced a follow-on offering of 4000000 shares of its common stock at a price to the ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Researchers Present Data That Support Inhaled Iloprost Therapy in … - May 23, 2005 Ventavis(R) (iloprost) Inhalation Solution was approved by the US Food and ... Ventavis is the newest entry into the prostacyclin class of PAH treatments. ... RedOrbit CoTherix, Inc. Reports Fourth Quarter and Year-End 2004 Results. - Mar 9, 2005 Completed recruitment of 23-person Ventavis sales force to reach the 500 to ... Ventavis is an inhaled formulation of iloprost, a synthetic compound that is ... $4.95 - PR Newswire - ECNext CoTherix, Inc. Reports Fourth Quarter and Year End 2005 Results. - Mar 8, 2006 Net product sales from the company's Ventavis(R) Inhalation Solution in the ... Total 2005 net product sales for Ventavis, which was launched in March 2005 ... Free with registration - PR Newswire - AccessMyLibrary.com National Institute for Health and Clinical Excellence (NICE) Releases... - Mar 3, 2008 Ventavis(R) (inhaled iloprost) has a vital role in bridging the gap between ... Ventavis(R) offers advantages over IV therapy in respect to convenience and ... ITNews National Institute for Health and Clinical Excellence (NICE) releases... - Mar 25, 2008 Ventavis(R) (inhaled iloprost) has a vital role in bridging the gap between ... Ventavis(R) offers advantages over IV therapy in respect to convenience and ... News-Medical.net Press Release: CoTherix Appoints Abhay Joshi as EVP and Chief … - Apr 11, 2006 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research Q1 2007 Actelion Earnings Conference Call - Final. - Apr 19, 2007 CoTherix has been successfully integrated and the sales of Ventavis are now on track with a very large increase of the salesforce effort on Ventavis after ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com MedImmune Inc. One MedImmune ... - May 1, 2006 Ventavis, made by CoTherix Inc., hit the market in March 2005. ... Inhaled Remodulin could eventually leapfrog Ventavis in sales because Remodulin will ... Pay-Per-View - Washington Post - ProQuest Archiver Press Release: Actelion Announces Definitive Agreement to Acquire US-... - Nov 20, 2006 In 2007, Actelion expects Ventavis(R) sales to contribute more than USD 100 ... CoTherix is developing Ventavis for the ... and Australia by Schering AG. ... Pay-Per-View - PR Newswire - HighBeam Research Q4 2005 COTHERIX INC Earnings Conference Call - Part 1. - Mar 8, 2006 Then, Tom will provide you with detail related to the fourth quarter sales of Ventavis, and finally, Don will take you through the highlights of the quarter ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Algunos medicamentos fueron desarrollados para el tratamiento de … - Dec 5, 2008 Antes del uso del viagra y ventavis la sobrevida era prácticamente nula. ... Hace cinco año el ventavis comenzó a comercializarse, asà que la pastilla azul ... El Diario de Yucatán Press Release: CoTherix to Initiate Clinical Registry to Study... - Oct 24, 2005 CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Article: CoTherix Announces Fourth Quarter Ventavis Sales and 2006 ... ... Pay-Per-View - PR Newswire - HighBeam Research Business & Finance; CoTherix reports sales from Vantavis Inhalation … - May 31, 2006 Net product sales from the company's Ventavis Inhalation Solution in the first ... Achieved first quarter Ventavis net sales of $14.5 million, resulting in ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Article: Actelion to buy CoTherix: $420 MILLION DEAL PUTS TWO … - Nov 21, 2006 Article: CoTherix Gets Approval For Inhaled PAH Drug Ventavis. ... Allschwil, Switzerland-based Actelion Ltd. CoTherix is studying Ventavis in combination . ... Pay-Per-View - San Jose Mercury News - HighBeam Research Press Release: National Institute for Health and Clinical Excellence... - Mar 3, 2008 Ventavis(R) (inhaled iloprost) has a vital role in bridging the gap between ... Ventavis(R) offers advantages over IV therapy in respect to convenience and ... Pay-Per-View - PR Newswire Europe - HighBeam Research Sleep Hldg Inc acquires Sleep Business Solutions LLC - Deal Snapshot ... - Mar 6, 2007 Renin Inhibitor Ventavis (Iloprost Inhalation Solution) Allon Therapeutics Inc. ( NPC:CA…Smart Amp (Heparin Lock Flush Solution) Barr Pharmaceuticals, ... Pay-Per-View - deals - Alacra Store … Announce Launch of New Portable Inhalation Device to Ventavis … - Dec 13, 2005 Ventavis is indicated for the treatment of pulmonary arterial hypertension ... Ventavis is marketed by CoTherix in the U.S. for the treatment of pulmonary . ... Pay-Per-View - PR Newswire - HighBeam Research United Therapeutics' Profit Surges - Feb 22, 2006 Ventavis, made by CoTherix Inc., hit the market in March 2005. "I think that certainly Ventavis is probably having some degree of impact on Remodulin sales ... Washington Post Press Release: CoTherix to Webcast Presentations From Three … - May 19, 2005 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Researchers Present Data That Support Inhaled Iloprost... - May 23, 2005 Ventavis(R) (iloprost) Inhalation Solution was approved by the U.S. Food and Drug Administration ... Article: New Ventavis Data Presented at CHEST Meeting. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix to Webcast Presentation From Merrill Lynch … - Jan 30, 2006 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix to Webcast Presentations From Two Upcoming … - Oct 29, 2005 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix Appoints Howard B. Rosen to Board of Directors... - Sep 19, 2005 CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Article: CoTherix Announces Fourth Quarter Ventavis Sales and 2006 ... ... Pay-Per-View - PR Newswire - HighBeam Research United Therapeutics Shares Soar on FDA Report - Nov 2, 2007 It has competition for its new drug, from an inhaled treatment called Ventavis that is marketed by Actelion Pharmaceuticals, a California drug company. ... Washington Post United Therapeutics' Profit Surges; But 4th-Quarter Figures Fall... - Feb 22, 2006 Ventavis, made by CoTherix Inc., hit the market in March 2005. "I think that certainly Ventavis is probably having some degree of impact on Remodulin sales ... Pay-Per-View - Washington Post - HighBeam Research First inhaled prostacyclin for pulmonary hypertension. - Feb 21, 2005 Iloprost (Ventavis, CoTherix) inhalation solution is indicated for the ... Vital signs should be monitored while initiating treatment with Ventavis, ... $9.94 - Drug Topics - Alacra Store Press Release: CoTherix to Webcast Presentations From Two Upcoming … - Mar 23, 2006 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research Q4 2005 COTHERIX INC Earnings Conference Call - Part 2. - Mar 8, 2006 So in order to give us a real world look at the addition of Ventavis on to Sildenafil, we proposed that we use basically stable Sildenafil dosing, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com NICE releases appraisal consultation document on treatment of … - Mar 6, 2008 Ventavis(R) offers advantages over IV therapy in respect to convenience and ... It does not evaluate the subgroup in which Ventavis(R) is actually used in ... Healthcare Republic - Healthcare Republic Press Release: CoTherix, Inc. Reports Fourth Quarter and Year End... - Mar 8, 2006 Net product sales from the company's Ventavis(R) Inhalation Solution in the ... Total 2005 net product sales for Ventavis, which was launched in March 2005 ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix, Inc. Announces Partial Exercise of Over- … - Feb 15, 2005 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix to Webcast Presentations From Two Upcoming … - Mar 29, 2005 Ventavis is an inhaled formulation of iloprost, a synthetic compound that ... CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a ... Pay-Per-View - PR Newswire - HighBeam Research ФинанÑ?овые новоÑ?ти архив - Nov 20, 2006 Ключевым продуктом компании CoTherix Ñ?влÑ?етÑ?Ñ? препарат Ventavis, ... По прогнозам компании Actelion, объем продаж Ventavis в 2007 году превыÑ?ит $100 млн. ... K2Kapital å?°ç?£å?¥ä¿?支æŒ?è‚ºå‹•è„ˆé«˜å£“ç—‡ç ”ç©¶ä»¤ä»–åœ‹æ¬½ç¾¨ - Jun 30, 2006 ...å¾?紹勛說，在先é?ˆå…¬å?¸ç ”發出é€?é?Žå?¸å…¥æ²»ç™‚的藥劑Ventavis後，å?°ç?£æ–¼2002年以é‡?大罕見 ç–¾ç—…å°ˆæ¡ˆç”³è«‹å¼•é€²ï¼Œç—…äººä¹Ÿå› ç‚ºæ–¹ä¾¿ä½¿ç”¨è€Œæ›´é¡˜æ„?接å?—æ²»ç™‚ï¼Œå› æ¤å˜æ´»çŽ‡å¾žé?ŽåŽ»ä¸? ... epochtimes.com Press Release: Biotech Ends the Year on a High Note; ... Raising More... - Jan 5, 2005 CoTherix is developing Ventavis for the treatment ... ... Technical Operations of CoTherix, Inc. "Ventavis is ... developed over the last 10 years to help ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: First Patient Enrolled in CoTherix REVEAL Registry. -... - Apr 4, 2006 Article: CoTherix Announces Fourth Quarter Ventavis Sales and 2006 . ... REVEAL ... commercialization of Ventavis, the REVEAL Registry and general corporate ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix, Inc. Announces Underwriters' Exercise of... - Oct 19, 2005 Article: CoTherix Announces Fourth Quarter Ventavis Sales and 2006 ... ... Article: CoTherix Initiates Trial of Ventavis in Combination With ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CoTherix Files Registration Statement for Follow-On … - Sep 20, 2005 Article: CoTherix Announces Fourth Quarter Ventavis Sales and 2006 ... ... Article: CoTherix Initiates Trial of Ventavis in Combination With ... ... Pay-Per-View - PR Newswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |